LitAlert ~~ GeneLit.com

    • PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
    • Collet L, Péron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, You B.
    • Cancers (Basel). 2022 Jan 25;14(3):599. doi: 10.3390/cancers14030599.
    • Population-Based Penetrance of Deleterious Clinical Variants.
    • Forrest IS, Chaudhary K, Vy HMT, Petrazzini BO, Bafna S, Jordan DM, Rocheleau G, Loos RJF, Nadkarni GN, Cho JH, Do R.
    • JAMA. 2022 Jan 25;327(4):350. doi: 10.1001/jama.2021.23686.

    Press: Chance Most “Pathogenic” Variants Will Actually Cause Disease Is Low. (Inside Precision Medicine)